Phaseolus vulgaris and α-amylase inhibition

Obesity: Epidemiology, Pathophysiology, and Prevention

Volumn , Issue , 2007, Pages 423-431

  Meiss, Dennis E ^a  

^a ProThera Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951557705     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (47)

1. Mokdad, A.H. et al., The spread of the obesity epidemic in the United States, JAMA, 282, 1519-1522, 1999.
2. Mokdad, A.H. et al., The continuing epidemics of obesity and diabetes in the United States, JAMA, 286, 1195-1200, 2001.
3. Nicklas, T.A. et al., Eating patterns, dietary quality and obesity, J. Am. Coll. Nutr., 20, 599-608, 2001.
4. Berkowitz, R.I. et al., Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial, JAMA, 289, 1851-1853, 2003.
5. Rea, T.D. et al., Body mass index and the risk of recurrent coronary events following acute myocardial infarction, Am. J. Cardiol., 1, 88, 467-472, 2001.
6. Young, S.Y. et al., Body mass index and asthma in the military population of the northwestern United States, Arch. Intern. Med., 161, 1605-1611, 2001.
7. Hansen, B., Emerging strategies for weight management, Postgrad. Med., June Special Report, 3-9, 2001.
8. Hensrud, D., Pharmacotherapy for obesity, Med. Clin. North Am., 84, 463-476, 2000.
9. Heber, D., Herbal preparations for obesity: are they useful?, Prim. Care, 30, 441-463, 2003.
10. Muls, E. et al., Is weight cycling detrimental to health? A review of the literature in humans, Int. J. Obes. Relat. Metab. Disord., 19(Suppl. 3), S46-S50, 1995.
11. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids, National Academy of Sciences, 2002, http://www.nap.edu/catalog/10490.html? onpi_newsdoc090502.
12. Andoh, A., Tsujikawa, T., and Fujiyama, Y., Role of dietary fiber and short-chain fatty acids in the colon, Curr. Pharm. Des., 9, 347-358, 2003.
13. Cummings, J.H. and Englyst, H.N., Measurement of starch fermentation in the human large intestine, Can. J. Physiol. Pharmacol., 69, 121-129, 1991.
14. 2 breath test can be used to assess starch digestion and fermentation in humans, J. Nutr., 134, 1193-1196, 2004.
15. Guyton, A.C. and Hall, J.E., Textbook of Medical Physiology, Ninth ed., WB Saunders, Philadelphia, PA, 1996, chap. 2.
16. Whitaker, J.R., α-Amylase inhibitors of higher plants and microorganisms, in Food Proteins, Soucie, W.G., Ed., American Oil Chemists Society, Champaign, IL, 1989, chap. 20.
17. Lajolo, F.M., Filho, F.F., and Menezes, E.W., Amylase inhibitors in Phaseolus vulgaris beans, Food Technol., Sept., 119-121, 1991.
18. Nakaguchi, T. et al., Structural characterization of an α-amylase inhibitor from a wild common bean (Phaseolus vulgaris): insight into the common structural features of leguminous α-amylase inhibitors, J. Biochem., 121, 350-354, 1997.
19. Santimone, M. et al., Porcine pancreatic α-amylase inhibition by the kidney bean (Phaseolus vulgaris) inhibitor (α-AI1) and structural changes in the α-amylase inhibitor complex, Biochim. Biophys. Acta, 1696, 181-190, 2004.
20. Payan, F., Structural basis for the inhibition of mammalian and insect α-amylases by plant protein inhibitors, Biochim. Biophys. Acta, 1696, 171-180, 2004.
21. Marshall, J.J. and Lauda, C.M., Purification and properties of phaseolamin, an inhibitor of alphaamylase, from the kidney bean, Phaseolus vulgaris, J. Biol. Chem., 250, 8030-8037, 1975.
22. Bo-Linn, G.W. et al., Starch blockers: their effect on calorie absorption from a high-starch meal, N. Engl. J. Med., 307, 1413-1416, 1982.
23. Hollenbeck, C.B. et al., Effects of a commercial starch blocker preparation on carbohydrate digestion and absorption: in vivo and in vitro studies, Am. J. Clin. Nutr., 38, 498-503, 1983.
24. 13C-enriched starch as a tracer, Hum. Nutr. Clin. Nutr., 37, 301-305, 1983.
25. Carlson, G.L. et al., A bean alpha-amylase inhibitor formulation (starch blocker) is ineffective in man, Science, 219, 393-395, 1983.
26. U.S. Food and Drug Administration, In the Matter of the Complaint Against General Nutrition Corporation General Nutrition Centers, 12-14-1983, 10-31-1983.
27. Layer, P., Carlson, G.L., and DiMagno, E.P., Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans, Gastroenterology, 88, 1895-1902, 1985.
28. Layer, P., Zinsmeister, A.R., and DiMagno, E.P., Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans, Gastroenterology, 91, 41-48, 1986.
29. Layer, P. et al., Effect of a purified amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes mellitus, Mayo Clin. Proc., 61, 442-447, 1986.
30. Boivin, M. et al., Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans, Mayo Clin. Proc., 62, 249-255, 1987.
31. Brugge, W.R. and Rosenfeld M.S., Impairment of starch absorption by a potent amylase inhibitor, Am. J. Gastroenterol., 82, 718-722, 1987.
32. Boivin, M. et al., Gastrointestinal and metabolic effects of amylase inhibition in diabetics, Gastroenterology, 94, 387-394, 1988.
33. Jain, N.K. et al., Effect of ileal perfusion of carbohydrates and amylase inhibitor on gastrointestinal hormones and emptying, Gastroenterology, 96, 377-387, 1989.
34. Birketveldt, G.S. et al., Dietary supplementation with bean extract improves lipid profile in overweight and obese subjects, Nutrition, 18, 729-733, 2002.
35. Pharmachem Laboratories, Inc., Kearney, NJ (unpublished results).
36. Vinson, J.A., In vivo effectiveness of a starch absorption blocker in a double-blind placebo-controlled study with normal human subjects, University of Scranton, 2001 (unpublished data).
37. Vinson, J.A., In vivo effectiveness of a starch absorption blocker in a double-blind placebo-controlled study with normal college-age subjects, University of Scranton, 2001 (unpublished data).
38. Vinson, J.A., Dose-response pilot study of Phase 2® efficacy as an inhibitor of glucose absorption with a full meal, University of Scranton, 2004 (unpublished data).
39. Thom, E., A randomized, double-blind, placebo-controlled trial of a new weight-reducing agents of natural origin, J. Int. Med. Res., 28, 229-233, 2000.
40. Downs, B.W. et al., Bioefficacy of a novel calcium-potassium salt of (-)-hydroxycitric acid, Mutat. Res., 579, 149-162, 2005.
41. Udani, J., Hardy, M., and Madsen, D., Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2® brand proprietary fractionated white bean extract, Alt. Med. Rev., 9, 63-69, 2004.
42. Meiss, D.E., Effect of a dietary supplement containing Phase 2® standardized Phaseolus vulgaris extract on the body composition of overweight men and women, manuscript in preparation, 2007.
43. Erner, S.I. and Meiss, D.E., Manuscript in preparation, 2007.
44. Harikumar, K.B. et al., A preliminary assessment of the acute and subchronic toxicity profile of Phase 2: an alpha-amylase inhibitor, Int. J. Toxicol., 24, 95-102, 2005.
45. Chokshi, D., Toxicity studies of Blockal, a dietary supplement containing Phase 2 Starch Neutralizer (Phase 2), a standardized extract of the common white kidney bean (Phaseolus vulgaris), Int. J. Toxicol., 25, 361-371, 2006.
46. Chokshi, D., Subchronic oral toxicity of a standardized white kidney bean (Phaseolus vulgaris) extract in rats, Food Chem. Toxicol., 2006 (epub ahead of print).
47. Information for Patients, Product Insert PD500024, Bayer Corp., Berkeley, CA, 1995.